6.1
The Committee recommends that further research should be conducted comparing available anti-tumour necrosis factor (TNF) agents (such as adalimumab, etanercept and infliximab) with each other.
The Committee recommends that further research should be conducted comparing available anti-tumour necrosis factor (TNF) agents (such as adalimumab, etanercept and infliximab) with each other.